Dr. Alan Tan
Claim this profileRush University Medical Center
Studies Cancer
Studies Renal Cell Carcinoma
14 reported clinical trials
25 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
TFEb positive
2Renal Cell Carcinoma
Stage IV
TFEb positive
TFE3 positive
Affiliated Hospitals
Clinical Trials Alan Tan is currently running
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria
Immunotherapy + Targeted Therapy
for Genitourinary Cancers
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Recruiting1 award Phase 221 criteria
More about Alan Tan
Clinical Trial Related4 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Alan Tan has experience with
- Nivolumab
- Ipilimumab
- Pembrolizumab
- Avelumab
- Cabozantinib
- Axitinib
Breakdown of trials Alan Tan has run
Cancer
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alan Tan specialize in?
Alan Tan focuses on Cancer and Renal Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Alan Tan currently recruiting for clinical trials?
Yes, Alan Tan is currently recruiting for 5 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Alan Tan has studied deeply?
Yes, Alan Tan has studied treatments such as Nivolumab, Ipilimumab, Pembrolizumab.
What is the best way to schedule an appointment with Alan Tan?
Apply for one of the trials that Alan Tan is conducting.
What is the office address of Alan Tan?
The office of Alan Tan is located at: Rush University Medical Center, Chicago, Illinois 60612 United States. This is the address for their practice at the Rush University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.